Portal vein thrombosis, a complication of cirrhosis, has an annual incidence of 4% in Spain, with risk factors being use of beta-blockers and hepatic encephalopsy, investigators reported during The Liver Meeting® 2015.
Among patients with HIV and hepatitis C virus (HCV) co-infection, daclatasvir and sofosbuvir is associated with a superior 12-week sustained virologic response (SVR12) rate compared to sofosbuvir and ribavirin, according to a systematic review of clinical trial data, reported at the The Liver Meeting® 2015.
Sorafenib was associated with a modest survival benefit in patients with advanced hepatocellular carcinoma (HCC), particiularly in patients with decompensation, data presented at The Liver Meeting® 2015 presented.
Second-line tacrolimus (Tac) or mycophenylate mofetil (MMF) therapy achieves complete or partial responses in most patients with autoimmune hepatitis (AIH) who developed intolerance or disease resistance to first-line azathioprine (AZA), according to a retrospective study reported at the The Liver Meeting® 2015.
Treatment with extended release naltrexone/bupropion (NB) for weight loss significantly improved and normalized serum ALT levels in obese and overweight individuals at high risk for non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes, reported Allison Winokur, PhD, from Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, at The Liver Meeting® 2015.
Peginterferon alfa-2b (Pegberon) demonstrates non-inferior efficacy to peginterferon alfa-2a (PEG IFNα-2a) for the treatment of Chinese HBeAg-positive chronic hepatitis B (CHB) patients, reported Gui-Qiang Wang, MD, PhD, from Peking University First Hospital, Beijing, China, at The Liver Meeting® 2015.
Combination treatment with peginterferon alfa-2a (peg-IFN) and adefovir or tenofovir for 48 weeks results in a loss and greater decline in HBsAg compared to no treatment in chronic hepatitis B (CHB) patients with a low viral load (LVL), reported Annikki de Niet, MD, from Academic Medical Center, Amsterdam, Netherlands, at The Liver Meeting® 2015.
The benefits of eradicating hepatitis C virus (HCV) infection with sofosbuvir may go well beyond avoiding the damage caused by chronic liver inflammation, to include declines in glycated hemoglobin (HbA1c) and other metabolic parameters, according to a study reported at The Liver Meeting® 2015.
Statin use and liver cancer were independently associated with older age, race, higher prevalence of diabetes, liver cirrhosis, smoking, BMI, and more total healthcare utilization, a study reported at The Liver Meeting® 2015.
Biologic agents are associated with “significantly higher” risk of hepatitis B virus (HBV) flares than non-biologic disease-modifying antirheumatic drugs (nbDMARDs) among patients with rheumatoid arthritis (RA) or psoriasis, according to a study reported at The Liver Meeting® 2015.
